<DOC>
	<DOCNO>NCT01160744</DOCNO>
	<brief_summary>The purpose study determine participant Stage IV NSCLC well outcome treat IMC-1121B combination pemetrexed + carboplatin/cisplatin gemcitabine + carboplatin/cisplatin treat pemetrexed + carboplatin/cisplatin gemcitabine + carboplatin/cisplatin alone .</brief_summary>
	<brief_title>A Study Pemetrexed Carboplatin/Cisplatin Gemcitabine Carboplatin/Cisplatin With Without IMC-1121B Participants Previously Untreated With Recurrent Advanced Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Confirmed NSCLC Stage IV disease time study entry Measurable disease time study entry Resolution Grade ≤ 1 Adverse Events , clinically significant toxic effect prior chemotherapy , surgery , radiotherapy , hormonal therapy ( except alopecia ) Adequate hematologic function , hepatic function , renal function coagulation function If sexually active , must postmenopausal , surgically sterile , use effective contraception ; agree use adequate contraception study period 6 month last dose study medication Female participant childbearing potential must negative serum pregnancy test Has cirrhosis level ChildPugh B ( bad ) , cirrhosis history hepatic encephalopathy , ascites result cirrhosis require ongoing treatment diuretic and/or paracentesis Tumor wholly partially contain small cell lung cancer Untreated central nervous system ( CNS ) metastases , eligible clinically stable regard neurologic function , steroid cranial irradiation least 2 week prior surgical resection perform least 4 week prior randomization Concurrent active malignancy adequately treat basal cell carcinoma skin preinvasive carcinoma cervix . A participant previous history malignancy NSCLC eligible , provide he/she free disease ≥ 3 year Received prior therapy monoclonal antibody , signal transduction inhibitor , therapy target vascular endothelial growth factor ( VEGF ) vascular endothelial growth factor receptor ( VEGFR ) Receiving concurrent treatment anticancer therapy Has receive previous chemotherapy Stage IV NSCLC ( participant receive adjuvant chemotherapy eligible last administration prior adjuvant regimen occur least 6 month prior randomization ) Has radiologically document evidence major blood vessel invasion encasement cancer Has undergone chest irradiation within 12 week prior randomization ( except palliative irradiation bone lesion ) Ongoing active infection History significant neurological psychiatric disorder Experienced clinically relevant coronary artery disease , myocardial infarction within 6 month prior randomization , uncontrolled congestive heart failure , symptomatic poorly control arrhythmia Poorlycontrolled hypertension Experienced serious Grade 34 gastrointestinal bleeding within 3 month prior study entry Receiving chronic daily treatment aspirin ( &gt; 325 mg/day ) know inhibitor platelet function Serious nonhealing wound , ulcer , bone fracture within 28 day prior randomization Major surgery within 28 day prior first dose study medication , subcutaneous venous access device placement within 7 day prior randomization Elective plan major surgery Pregnant lactate Any serious uncontrolled medical disorder psychological condition Allergy / history hypersensitivity reaction treatment component History drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Lung neoplasm</keyword>
	<keyword>Lung cancer</keyword>
	<keyword>Non-small Cell Lung Cancer</keyword>
	<keyword>pemetrexed</keyword>
	<keyword>ALIMTA®</keyword>
	<keyword>squamous</keyword>
	<keyword>nonsquamous</keyword>
</DOC>